CA3066874A1 - Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus - Google Patents

Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus Download PDF

Info

Publication number
CA3066874A1
CA3066874A1 CA3066874A CA3066874A CA3066874A1 CA 3066874 A1 CA3066874 A1 CA 3066874A1 CA 3066874 A CA3066874 A CA 3066874A CA 3066874 A CA3066874 A CA 3066874A CA 3066874 A1 CA3066874 A1 CA 3066874A1
Authority
CA
Canada
Prior art keywords
cardiovascular
disease
patient
history
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3066874A
Other languages
English (en)
French (fr)
Inventor
Norman R. Rosenthal
Douglas K. Ways
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA3066874A1 publication Critical patent/CA3066874A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
CA3066874A 2017-06-12 2018-06-11 Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus Pending CA3066874A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762518547P 2017-06-12 2017-06-12
US62/518,547 2017-06-12
PCT/IB2018/054208 WO2018229630A1 (en) 2017-06-12 2018-06-11 Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus

Publications (1)

Publication Number Publication Date
CA3066874A1 true CA3066874A1 (en) 2018-12-20

Family

ID=62916717

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3066874A Pending CA3066874A1 (en) 2017-06-12 2018-06-11 Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus

Country Status (15)

Country Link
US (2) US20180353470A1 (enExample)
EP (1) EP3638250A1 (enExample)
JP (2) JP2020523408A (enExample)
KR (1) KR20200014406A (enExample)
CN (1) CN110740735A (enExample)
AU (1) AU2018283781B2 (enExample)
BR (1) BR112019026120A2 (enExample)
CA (1) CA3066874A1 (enExample)
CO (1) CO2019013940A2 (enExample)
EA (1) EA202090028A1 (enExample)
IL (1) IL271100A (enExample)
MX (1) MX2019014988A (enExample)
TW (1) TWI835735B (enExample)
UA (1) UA127987C2 (enExample)
WO (1) WO2018229630A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI827184B (zh) * 2021-08-03 2023-12-21 國立政治大學 第2型糖尿病併發症的風險評估系統與方法
CN117085009B (zh) * 2023-10-20 2024-01-30 首都医科大学附属北京天坛医院 卡格列净对急性缺血性卒中的治疗作用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104109155A (zh) 2003-08-01 2014-10-22 田边三菱制药株式会社 新颖化合物
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
ES2455124T5 (es) * 2010-05-05 2018-05-08 Zora Biosciences Oy Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca
JP5596799B2 (ja) * 2010-05-11 2014-09-24 田辺三菱製薬株式会社 カナグリフロジン含有錠剤
US20160000816A1 (en) * 2013-04-05 2016-01-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN105939728A (zh) * 2014-01-31 2016-09-14 詹森药业有限公司 用于治疗和预防肾病和脂肪肝病的方法
US20170071970A1 (en) * 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Also Published As

Publication number Publication date
TWI835735B (zh) 2024-03-21
US20210000792A1 (en) 2021-01-07
EA202090028A1 (ru) 2020-04-03
AU2018283781B2 (en) 2023-09-28
CN110740735A (zh) 2020-01-31
US20180353470A1 (en) 2018-12-13
KR20200014406A (ko) 2020-02-10
JP2023113644A (ja) 2023-08-16
MX2019014988A (es) 2020-08-06
AU2018283781A1 (en) 2019-12-19
JP2020523408A (ja) 2020-08-06
BR112019026120A2 (pt) 2020-07-07
UA127987C2 (uk) 2024-03-06
WO2018229630A1 (en) 2018-12-20
TW201904584A (zh) 2019-02-01
IL271100A (en) 2020-01-30
EP3638250A1 (en) 2020-04-22
CO2019013940A2 (es) 2020-01-17

Similar Documents

Publication Publication Date Title
O’Hara et al. Applications of SGLT2 inhibitors beyond glycaemic control
JP7020756B2 (ja) 対象の心血管イベントのリスクを低減する方法
Sakai et al. Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction―novel prospective cohort study―
Zambrowicz et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes
Janez et al. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group
JP2019508453A (ja) エンパグリフロジンを含む医薬組成物及びその使用
RU2768283C2 (ru) Семаглутид при сердечно-сосудистых состояниях
CN109512831A (zh) 依帕列净的治疗用途
TW202108134A (zh) 利用達格列淨治療射血分率降低的心臟衰竭之方法
Mazza et al. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: from clinical trials to real-world settings
Lee et al. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study
CN117677395A (zh) 长效glp1/胰高血糖素受体激动剂的剂量方案
JP2023113644A (ja) ２型糖尿病の患者における心血管イベントの低減又は予防方法
JP2025041648A (ja) 心血管有害事象のリスクのある対象における鉄欠乏症の処置
Seoudy et al. Gliflozins for the treatment of congestive heart failure and renal failure in type 2 diabetes
US20150065421A1 (en) Basal insulin therapy
JP2020523408A5 (enExample)
Roy Administration of once-daily canagliflozin to a non-diabetic patient in addition to standard aerobic exercise: a case report
HK40021204A (en) Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
Oommen et al. Droxidopa for hypotension of different etiologies: two case reports
WO2025233434A1 (en) Effect of intravenous ferric carboxymaltose on exercise capacity in symptomatic patients with heart failure and a preserved ejection fraction with iron deficiency with and without anaemia
CN102068441A (zh) 一种含有替米沙坦和格列美脲的复方制剂
Al-Harbi An open-label, uncontrolled study to evaluate the effect of verapamil on glycaemic control in type 2 diabetes mellitus patients with hypertension
Kavanagh Antihypertensive drugs
Abdullah et al. Sodium-Glucose Cotransporter-2 Inhibitors: Who, When & How? Guidance for Use from a Multidisciplinary Practical Approach

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220919

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240919

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241018

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241227

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250109

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251031

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251031

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251031

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260723